Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BRACE trial

- PMLiVE

EU aims to vaccinate 40% of population in initial COVID-19 blueprint

Target is double the goal set by the World Health Organization

- PMLiVE

Novavax CEO anticipates filing COVID-19 vaccine for approval in December

Pfizer also announces over 50% enrolment in COVID-19 vaccine trial

- PMLiVE

Moderna’s COVID-19 vaccine shows promise in older adults

Early trial data from small group is encouraging

- PMLiVE

COVID-19 vaccine deals with the EU hindered by strict liability rules

Companies would retain liability for unexpected side effects

Sanofi reception

Translate Bio, Sanofi’s COVID-19 vaccine proves promising in animal studies

Vaccine was able to induce neutralising antibodies and T-cell responses

- PMLiVE

EU concludes discussions with Moderna for COVID-19 vaccine

Biotech company on the verge on finalising supply deal

- PMLiVE

Novavax begins phase 2 portion of COVID-19 vaccine trial

Trial will enrol up to 1,500 participants in the US and Australia

- PMLiVE

COVID-19 vaccine ‘unlikely’ to be available this year, says UK’s chief medical officer

Chris Whitty warns that there is no certainty that an effective vaccine will be available before winter 2021

- PMLiVE

FDA grants emergency approval for blood plasma treatments for COVID-19

Emergency approval granted despite concerns from top US health officials

- PMLiVE

Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

Companies share additional phase 1 safety and tolerability data

- PMLiVE

US payments for COVID-19 vaccines tied to specific timing milestones

Full pay-out is dependent on achieving regulatory approval by certain dates

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links